Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model
A new series of potent nonpeptide vitronectin receptor antagonists, based on a novel carbocyclic Gly-Asp mimetic, has been discovered. A representative of this series, SB 265123 (4), has 100% oral bioavailability in rats, and is orally active in vivo in the ovariectomized rat model of osteoporosis.
References (47)
Int. J. Biochem. Cell Biol.
(1997)- et al.
Curr. Biol.
(1994) - et al.
Exp. Cell Res.
(1991) - et al.
J. Vasc. Surgery
(1994) - et al.
Cell
(1994) - et al.
Bioorg. Med. Chem. Lett
(1998) - et al.
Bioorg. Med. Chem. Lett
(1998) - et al.
Bioorg. Med. Chem. Lett.
(1999) - et al.
Bioorg. Med. Chem. Lett.
(1997) - et al.
Tetrahedron Lett.
(1992)
Bioorg. Med. Chem. Lett.
(1994)
J. Biol. Chem.
(1997)
Ann. Rep. Med. Chem.
(1996)
Current Pharmaceutical Design
(1997)
Angew. Chem. Int. Ed. Engl.
(1997)
J. Biol. Chem.
(1994)
J. Bone Mineral Res.
(1994)
J. Bone Mineral Res.
(1992)
J. Bone Mineral Res.
(1992)
Circulation
(1994)
Circ. Res.
(1994)
Science
(1995)
Science
(1994)
Cited by (43)
R-Isomers of Arg-Gly-Asp (RGD) mimics as potent α<inf>v</inf>β<inf>3</inf> inhibitors
2007, Bioorganic and Medicinal ChemistryPromotion of skin epithelial cell migration and wound healing by a 2-benzazepine derivative
2007, European Journal of PharmacologyInhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics
2007, Bioorganic and Medicinal Chemistry Letters
Copyright © 1999 Published by Elsevier Ltd.